The Dutch government has pledged to provide 45.0 million euros ($62.4 million) to the BioMedical Materials program which has been initiated by DSM and the University of Maastricht. BMM is a five-year public-private partnership in the Netherlands that focuses on R&D in the field of biomedical materials and has a provisional budget of 90.0 million euros.
BMM's mission is to further strengthen the Netherlands' position in the field of biomedical materials by developing successful medical applications, obtaining intellectual property rights and publishing scientific papers. Besides DSM and the University of Maastricht, leading players in the consortium include Philips Research, Organon, Medtronic, FUJIFILM Life Science, Pharming, TNO (the Dutch Organization for Applied Scientific Research) and most of the leading universities and university medical centers in the Netherlands.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze